Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ole Kirk

Showing results (71-80 of 171) with videos related to

Pageof 18
Sort By:
AIDS (London, England)|April 28, 2011
Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA studyJean-Paul Viard, Jean-Claude Souberbielle, Ole Kirk, et al.
Antiviral Therapy|September 28, 2012
The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppressionAmanda Mocroft, Wendy P Bannister, Ole Kirk, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 9, 2006
Regional changes over time in initial virologic response rates to combination antiretroviral therapy across EuropeWendy P Bannister, Ole Kirk, Jose M Gatell, et al.
Diabetes Research and Clinical Practice|April 28, 2022
Glucometabolic changes influence hospitalization and outcome in patients with COVID-19: An observational cohort studyClara L Clausen, Christian Leo-Hansen, Daniel Faurholt-Jepsen, et al.
AIDS (London, England)|January 16, 2008
Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDAWendy P Bannister, Lidia Ruiz, Alessandro Cozzi-Lepri, et al.
Journal of the International AIDS Society|November 14, 2014
Predictive value of prostate-specific antigen for prostate cancer: a nested case-control study in EuroSIDALeah Shepherd, Alvaro Humberto Borges, Lene Ravn, et al.
AIDS (London, England)|August 28, 2007
Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-scoreAmanda Mocroft, Bruno Ledergerber, Kai Zilmer, et al.
AIDS (London, England)|December 24, 2013
Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive personsLene Ryom, Amanda Mocroft, Ole Kirk, et al.
BMC Infectious Diseases|September 27, 2012
Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA studyDaria N Podlekareva, Joanne Reekie, Amanda Mocroft, et al.
Antiviral Therapy|November 13, 2004
Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA studyCecilia Cabrera, Alessandro Cozzi-Lepri, Andrew N Phillips, et al.
Pageof 18

Showing results (71-80 of 171) with videos related to

Sort By:
Pageof 18
AIDS (London, England)|April 28, 2011
Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA studyJean-Paul Viard, Jean-Claude Souberbielle, Ole Kirk, et al.
Antiviral Therapy|September 28, 2012
The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppressionAmanda Mocroft, Wendy P Bannister, Ole Kirk, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 9, 2006
Regional changes over time in initial virologic response rates to combination antiretroviral therapy across EuropeWendy P Bannister, Ole Kirk, Jose M Gatell, et al.
Diabetes Research and Clinical Practice|April 28, 2022
Glucometabolic changes influence hospitalization and outcome in patients with COVID-19: An observational cohort studyClara L Clausen, Christian Leo-Hansen, Daniel Faurholt-Jepsen, et al.
AIDS (London, England)|January 16, 2008
Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDAWendy P Bannister, Lidia Ruiz, Alessandro Cozzi-Lepri, et al.
Journal of the International AIDS Society|November 14, 2014
Predictive value of prostate-specific antigen for prostate cancer: a nested case-control study in EuroSIDALeah Shepherd, Alvaro Humberto Borges, Lene Ravn, et al.
AIDS (London, England)|August 28, 2007
Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-scoreAmanda Mocroft, Bruno Ledergerber, Kai Zilmer, et al.
AIDS (London, England)|December 24, 2013
Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive personsLene Ryom, Amanda Mocroft, Ole Kirk, et al.
BMC Infectious Diseases|September 27, 2012
Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA studyDaria N Podlekareva, Joanne Reekie, Amanda Mocroft, et al.
Antiviral Therapy|November 13, 2004
Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA studyCecilia Cabrera, Alessandro Cozzi-Lepri, Andrew N Phillips, et al.
Pageof 18